Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia

Canadian Journal of Hospital Pharmacy

Volumn 68, Issue 4, 2015, Pages 296-303

  Batterink, Josh ^a   Lin, Jane ^a   Au Yeung, Sarah Hin Mui ^b,c   Cessford, Tara ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Nanaimo Regional General Hospital   (Colombia)

Author keywords

Hyperkalemia; Kayexalate; Sodium polystyrene sulfonate (SPS)

Indexed keywords

POLYSTYRENESULFONATE SODIUM; POTASSIUM;

AGED; ARTICLE; CLINICAL EVALUATION; CLOSTRIDIUM INFECTION; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG DOSE COMPARISON; DRUG EFFICACY; ENTEROCOLITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; INTESTINE NECROSIS; INTESTINE PSEUDOOBSTRUCTION; ISCHEMIC COLITIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PEPTOCLOSTRIDIUM DIFFICILE; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TERTIARY CARE CENTER;

EID: 84959512816     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v68i4.1469     Document Type: Article

References (26)

1. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158(8):917-24.
2. Moore ML, Bailey RR. Hyperkalaemia in patients in hospital. N Z Med J. 1989;102(878):557-8.
3. Shapiro S, Slone D, Lewis GP, Jick H. Fatal drug reactions among medical inpatients. JAMA. 1971;216(3):467-72.
4. Paice B, Gray JM, McBride D, Donnelly T, Lawson DH. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed). 1983;286(6372):1189-92.
5. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005; (2): CD003235.
6. Evans KJ, Greenberg A. Hyperkalemia: a review. J Intensive Care Med. 2005;20(5):272-90.
7. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733-5.
8. Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010;5(10):1723-6.
9. Drugs@FDA: FDA approved drug products. Silver Spring (MD): Food and Drug Administration (US); [cited 2013 Aug. 28]. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist
10. Drug product database online query. Ottawa (ON): Health Canada; 2012 [cited 2014 Aug. 8]. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/. Search term for product name: "Kayexalate".
11. Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol: a preliminary report. N Engl J Med. 1961;264(3):111-5.
12. Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;264(3):115-9.
13. Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol. 1998;9(10):1924-30.
14. Emmett M, Hootkins RE, Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology. 1995;108(3):752-60.
15. Kessler C, Ng J, Valdez K, Xie H, Geiger B. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011;6(3):136-40.
16. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e9-24.
17. Kidney Disease: Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138.
18. Kuwabara S, Misawa S, Kanai K, Tamura N, Nakata M, Sawai S, et al. The effects of physiological fluctuation of serum potassium levels on excitability properties in healthy human motor axons. Clin Neurophysiol. 2007;118(2):278-82.
19. Caliendo M, Kopeinig S. Some practical guidance for the implementation of propensity score matching. J Econ Surv. 2008;22(1):31-72.
20. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399-424.
21. Propensity score matching in observational studies. Winnipeg (MB): University of Manitoba, Faculty of Medicine, Manitoba Centre for Health Policy; [cited 2013 Jul. 4]. Available from: http://umanitoba.ca/faculties/medicine/units/community-health-sciences/departmental-units/mchp/protocol/media/propensity-score-matching.pdf
22. Heckman JJ, Ichimura H, Todd P. Matching as an econometric evaluation estimator. Rev Econ Stud. 1998;65(2):261-94.
23. Kayexalate (sodium polystyrene sulfonate) [package insert]. Laval (QC): Sanofi-Aventis Canada Inc; 2014.
24. Sodium polystyrene sulfonate. In: Lexi-drugs online [database on Internet]. Hudson (OH): Lexicomp, Inc; 2015 [updated 10 Feb. 2015; cited 10 Feb. 2015]. Available from: http://online.lexi.com. Subscription required to access content.
25. McGowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 2009;102(5):493.
26. Safety information: Kayexalate (sodium polystyrene sulfonate) powder. Silver Spring (MD): Food and Drug Administration (US); 2009 Sep. [cited 2012 Jul. 9]. Available from: www.fda.gov/Safety/MedWatch/Safety Information/ucm186845.htm